INSTI's For The Management of HIV-associated TB

Conditions:   HIV/AIDS;   Tuberculosis, Pulmonary Interventions:   Combination Product: Biktarvy®;   Combination Product: TLD- fixed-drug combination single tablet Sponsors:   Centre for the AIDS Programme of Research in South Africa;   Johns Hopkins University;   National Institute of Allergy and Infectious Diseases (NIAID);   University of Cape Town;   Medical Research Council, South Africa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news
Conditions:   HIV/AIDS;   Tuberculosis, Pulmonary Interventions:   Combination Product: Biktarvy®;   Combination Product: TLD- fixed-drug combination single tablet Sponsors:   Centre for the AIDS Programme of Research in South Africa;   Johns Hopkins University;   National Institute of Allergy and Infectious Diseases (NIAID);   University of Cape Town;   Medical Research Council, South Africa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractUltraviolet blood irradiation (UBI) was used with success in the 1930s and 1940s for a variety of diseases. Despite the success, the lack of understanding of the detailed mechanisms of actions, and the achievements of antibiotics, phased off the use of UBI from the 1950s. The emergence of novel viral infections, from HIV/AIDS to Ebola, from SARS and MERS, and SARS-CoV-2, bring back the attention to this therapeutical opportunity. UBI has a complex virucidal activity, mostly acting on the immune system response. It has effects on lymphocytes (T-cells and B-cells), macrophages, monocytes, dendritic cells, low-density...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Conditions:   HIV Infections;   Tuberculosis Interventions:   Drug: Bictegravir (BIC);   Drug: Tenofovir alafenamide (TAF);   Drug: Cabotegravir (CAB);   Drug: Dolutegravir (DTG);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Lopinavir/ritonavir (LPV/r);   Drug: Cobicistat;   Drug: Ritonavir;   Drug: First-Line TB Treatment;   Drug: Second-Line TB Treatment;   Drug: Doravirine (DOR) Sponsor...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   HIV/AIDS;   Tuberculosis Intervention:   Behavioral: Choice Architecture Sponsors:   Johns Hopkins University;   University of Witwatersrand, South Africa;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Allergy | Allergy & Immunology | HIV AIDS | Infectious Diseases | Research | South Africa Health | Tuberculosis